Glimican MV 303 Tablet SR is a combination oral hypoglycemic agent formulated to manage type 2 diabetes mellitus by improving glycemic control. It contains Glimepiride 3 mg, Metformin 500 mg, and Voglibose 0.3 mg, each contributing distinct mechanisms to regulate blood glucose levels. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing fasting and postprandial blood glucose. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, facilitating better glucose uptake in muscle tissues. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, attenuating postprandial hyperglycemia. The sustained-release (SR) formulation ensures gradual drug release, promoting consistent plasma concentrations and improved patient compliance. Glimican MV 303 is indicated for patients inadequately controlled on monotherapy or dual therapy with these agents, offering a comprehensive approach to glycemic management. It is essential to monitor renal and hepatic function periodically during therapy due to Metformin’s contraindications in renal impairment and the risk of lactic acidosis. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and mild allergic reactions. This combination should be used under medical supervision, with dosage adjustments tailored to individual patient response and tolerability.